Patients with NSCLC that are DDR mutants are associated with better clinical outcomes when treated with PD-(L)1 blockade, as DDR gene alterations correlate with an increase in tumor-infiltrating lymphocytes, genomic instability, TMB, and PD-L1 expression [67,72]. This evidence concerns the gene CD274 and neoplasm.